In addition, in the present study, the OSRR in intrahepatic lesions and MVTT was 32.8 and 54.5%, which is slightly higher than reported by Kuo and colleagues among patients with advanced HCC receiving anti-PD-1 antibody monotherapy (intrahepatic: 14.7%; MVTT: 50%) [16]. Here, PDCD1 is linked to hepatocellular carcinoma.